Zealand Pharma News and Activities
Presence
Headquarters: Denmark
Zealand Pharma is a company listed under the stock ticker ZEAL (DK).
Executives
View the org chart displaying its 41 main executives
Most searched biographies at Zealand Pharma
- Adam Steensberg, President and Chief Executive Officer
- Anneline Nansen, Director
- Kirsten Drejer, Vice Chairman of the Board
Popular executive movements at Zealand Pharma
- Camilla Sylvest has joined the company as Director (posted on May 4 2026).
- Eric Rojas has joined the company as Vice President and Head of Investor Relations (posted on April 15 2026).
- Rachel James Owens has joined the company as Vice President, Corporate Communications and Media Relations (posted on September 26 2025).
Create your alert
to follow the executive moves at Zealand Pharma.
Biotechnology
Zealand Pharma has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).
Popular M&A news in Biotechnology
- Laboratoire Servier has announced the acquisition of Edgewise Therapeutics (posted on June 4 2026).
- Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
- IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
Popular contacts in Biotechnology
News
Press releases by Zealand Pharma
- Zealand Pharma to participate in the Jefferies London Healthcare Conference
- Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
- Zealand Pharma Announces Financial Results for the First Nine Months of 2024
- Zealand Pharma conference call on November 7 at 2pm CET (8am ET) to present third quarter 2024 financial results
- Zealand Pharma announces that Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two Phase III trials in MASH for survodutide
- Zealand Pharma provides U.S. regulatory update on dasiglucagon in congenital hyperinsulinism
- Total number of shares and voting rights in Zealand Pharma A/S on September 30, 2024
- Zealand Pharma to participate in the 2024 Cantor Global Healthcare Conference on September 18th
- Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
- Zealand Pharma announces positive topline results from 13-week Phase 1b multiple ascending dose clinical trial with GLP-1/GLP-2 receptor dual agonist dapiglutide
- View more press releases Close
Social media about Zealand Pharma
- Zealand Pharma on Wikipedia, Google News & Yahoo Finance
- Zealand Pharma on LinkedIn, X (Twitter) & YouTube
